Cultural Adaptation of the TOMMORROW Cognitive Battery in Russia, Switzerland, and Italy, Clinical Trials on Alzheimer’s Disease, November 6, 2015. Alexandra S. Atkins (1); Adam W. Vaughan (1); Nicole M. Turcotte (1); Oksana A. Makeeva (2); Andreas U. Monsch (3); Giovanni B. Frisoni (4,10); Maura Parapini (4,10); Irina Zhukova (2); Zara Melikyan (11); Shyama Brewster (5); Kumar Budur (6); Janet O’Neil (6); Heather R. Romero (8); Brenda L. Plassman (7,8); Kathleen M. Hayden (7,8,9); Kathleen A. Welsh-Bohmer (7,8); and Richard S.E. Keefe (1,8).
1 NeuroCog Trials, Durham, NC, USA; 2 Neuropsychology Testing Center, Nebbiolo, LLC, Tomsk, Russia; 3 Memory Clinic, University Center for Medicine of Aging Basel, Felix Platter Hospital, Basel, Switzerland and University of Basel, Switzerland; 4 IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; 5 Zinfandel Pharmaceuticals Inc., Chapel Hill, NC, USA; 6 Takeda Development Center Americas, Inc., Deerfield, IL, USA; 7 Joseph and Kathleen Bryan ADRC, Duke University Medical Center, Durham, NC, USA; 8 Department of Psychiatry, Duke University Medical Center, Durham, NC, USA; 9 Department of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA; 10University Hospitals and University of Geneva, Geneva, Switzerland; 11 University of North Carolina at Wilmington, NC, USA
Cultural adaptation of cognitive assessments improves the quality of translated instruments by ensuring tasks, stimuli, and instructions are understood and are appropriate for use in populations of interest. We present methods and results from a comprehensive linguistic and cultural adaptation of the TOMMORROW cognitive battery, designed to detect transition from normal aging to mild cognitive impairment due to Alzheimer’s disease (MCI-AD) in multinational clinical trials.